Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Villalona-Calero

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Oncology (Williston Park, N.Y.)|December 1, 1995
New anticancer agents in clinical developmentJ Eckardt, G Eckhardt, M Villalona-Calero, et al.
Oncology (Williston Park, N.Y.)|November 1, 1995
New anticancer agents in clinical developmentJ Eckardt, G Eckhardt, M Villalona-Calero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2008
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)E Mrozek, J Kolesar, D Young, et al.
Leukemia|May 25, 2011
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridolK A Blum, A S Ruppert, J A Woyach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignanciesC D Britten, E K Rowinsky, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationJ Rodon, H Prenen, A Sacher, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Oncology (Williston Park, N.Y.)|December 1, 1995
New anticancer agents in clinical developmentJ Eckardt, G Eckhardt, M Villalona-Calero, et al.
Oncology (Williston Park, N.Y.)|November 1, 1995
New anticancer agents in clinical developmentJ Eckardt, G Eckhardt, M Villalona-Calero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2008
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)E Mrozek, J Kolesar, D Young, et al.
Leukemia|May 25, 2011
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridolK A Blum, A S Ruppert, J A Woyach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignanciesC D Britten, E K Rowinsky, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2024
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose explorationJ Rodon, H Prenen, A Sacher, et al.
Pageof 1